生物
等离子体电池
抗体
癌症研究
免疫疗法
肾细胞癌
癌症免疫疗法
癌症
免疫系统
肿瘤微环境
免疫检查点
免疫学
病理
医学
遗传学
作者
Maxime Meylan,Florent Petitprez,Étienne Becht,Antoine Bougouïn,Guilhem Pupier,Anne Calvez,Ilenia Giglioli,Virginie Verkarre,Guillaume Lacroix,Johanna Verneau,Chengming Sun,Pierre Laurent‐Puig,Yann Vano,Réza Elaidi,Arnaud Méjean,Rafael Sanchez‐Salas,Éric Barret,Xavier Cathelineau,Stéphane Oudard,Claude‐Agnès Reynaud,Aurélien de Reyniès,Catherine Sautès‐Fridman,Wolf H. Fridman
出处
期刊:Immunity
[Elsevier]
日期:2022-03-01
卷期号:55 (3): 527-541.e5
被引量:297
标识
DOI:10.1016/j.immuni.2022.02.001
摘要
The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial transcriptomics to examine the nature of B cell responses within TLS in renal cell carcinoma (RCC). B cells were enriched in TLS, and therein, we could identify all B cell maturation stages toward plasma cell (PC) formation. B cell repertoire analysis revealed clonal diversification, selection, expansion in TLS, and the presence of fully mature clonotypes at distance. In TLS+ tumors, IgG- and IgA-producing PCs disseminated into the tumor beds along fibroblastic tracks. TLS+ tumors exhibited high frequencies of IgG-producing PCs and IgG-stained and apoptotic malignant cells, suggestive of anti-tumor effector activity. Therapeutic responses and progression-free survival correlated with IgG-stained tumor cells in RCC patients treated with immune checkpoint inhibitors. Thus, intratumoral TLS sustains B cell maturation and antibody production that is associated with response to immunotherapy, potentially via direct anti-tumor effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI